Priced Oct 29, 2026 · range was $15–$17 · latest SEC filing Nov 6, 2026.
Pinch-zoom for details.
Clinical-stage drug developer working on long-acting bispecific antibodies for immunology and inflammation.
Fiscal year
1st half
Fiscal year
1st half
| $ | Period 2024 | FY2025 | YoY | H1 2025 | H1 2026 | Change |
|---|---|---|---|---|---|---|
| Operating result | (13.9M) | (44.0M) | n/m | (15.4M) | (24.1M) | −55.7% |
| Net result | (13.7M) | (41.1M) | n/m | (14.7M) | (22.4M) | −51.6% |
| $ | Period 2024 | FY2025 | YoY |
|---|---|---|---|
| Operating result | (13.9M) | (44.0M) | n/m |
| Net result | (13.7M) | (41.1M) | n/m |
| $ | H1 2025 | H1 2026 | Change |
|---|---|---|---|
| Operating result | (15.4M) | (24.1M) | −55.7% |
| Net result | (14.7M) | (22.4M) | −51.6% |
Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.
The filing's own risk-factor headings, shortened.
The filing's own strategy headings, shortened.
Source: Bambusa Therapeutics, Inc.'s Form 424B4, filed with the SEC on Oct 30, 2026 (final prospectus). Figures are as filed; changes are worked out from them. Not investment advice.
Pinch-zoom for details.
10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.
Infographic
Double-tap: full screen or back